The requirement of host response to IFN-I for the augmentation of tumor regression and T cell responses by CTX treatment was demonstrated in previous studies using IFNAR1 blockade with antibody [4] and Ifnar1−/− mice [12,13], respectively. Here, IFNAR1 is linked to neoplasm.